Mehdi Shahidi
- Pulmonary and Respiratory Medicine top 0.2%
- Oncology top 0.5%
- Molecular Biology top 5%
- Cancer Research top 2%
- Organic Chemistry top 5%
- Co-authors
- James Chih‐Hsin YangVera HirshWu‐Chou SuLecia V. SequistNobuyuki YamamotoMartin SchülerTony MokDan Massey
- Topics
- Lung Cancer Treatments and Mutations (17 papers)HER2/EGFR in Cancer Research (6 papers)Colorectal Cancer Treatments and Studies (6 papers)
- Partner nations
- United KingdomUnited StatesEgypt
In The Last Decade
Mehdi Shahidi
21 papers receiving 4.9k citations
Hit Papers
Peers
Comparison fields: 5 of 83
- Pulmonary and Respiratory Medicine 4.3k
- Oncology 3.6k
- Molecular Biology 1.6k
- Cancer Research 767
- Organic Chemistry 327
Countries citing papers authored by Mehdi Shahidi
This map shows the geographic impact of Mehdi Shahidi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mehdi Shahidi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mehdi Shahidi more than expected).
Fields of papers citing papers by Mehdi Shahidi
This network shows the impact of papers produced by Mehdi Shahidi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mehdi Shahidi. The network helps show where Mehdi Shahidi may publish in the future.
Co-authorship network of co-authors of Mehdi Shahidi
This figure shows the co-authorship network connecting the top 25 collaborators of Mehdi Shahidi. A scholar is included among the top collaborators of Mehdi Shahidi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mehdi Shahidi. Mehdi Shahidi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 30 | |
| 2 | Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutationsbreakdown → | 2461 |
| 3 | 22 | |
| 4 | 245 | |
| 5 | 266 | |
| 6 | Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialbreakdown → | 776 |
| 7 | 24 | |
| 8 | 332 | |
| 9 | 14 | |
| 10 | 11 | |
| 11 | 113 | |
| 12 | 295 | |
| 13 | Activity of BIBW 2992, an oral irreversible EGFR/HER2 dual kinase inhibitor, in combination with weekly paclitaxel in non-small cell lung cancer | 4 |
| 14 | Clinical activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2 in adenocarcinoma of the lung with mutations in the kinase domain of HER2neu | 20 |
| 15 | 14 | |
| 16 | A phase I dose finding study of a 3-day administration of BIBW 2992, an irreversible dual EGFR/HER2 inhibitor, in combination with 3-weekly docetaxel in patients with advanced solid tumors | 1 |
| 17 | 34 | |
| 18 | 49 | |
| 19 | 47 | |
| 20 | 86 |
About Mehdi Shahidi
Mehdi Shahidi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics, having authored 22 papers that have together received 5.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (17 papers), HER2/EGFR in Cancer Research (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). The work is most often cited by research in Oncology (3.6k citations), Pulmonary and Respiratory Medicine (4.3k citations) and Cancer Research (767 citations). Mehdi Shahidi has collaborated with scholars based in United Kingdom, United States and Egypt. Frequent co-authors include James Chih‐Hsin Yang, Vera Hirsh, Wu‐Chou Su, Lecia V. Sequist, Nobuyuki Yamamoto, Martin Schüler, Tony Mok, Dan Massey, Kenneth J. O’Byrne and Victoria Zazulina. Their work appears in journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.